G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer

NEXT STORY
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
PREV STORY
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Nanosphere Announces Record Preliminary Q4 and Full Year 2015 Results

Preliminary Fourth Quarter Revenue of $6.8 MillionPreliminary Full Year Revenue of $21.0 Million Exceeding ...

author_avatar
NASDAQ Market News

Oncology Venture A/S establish a flexible loan facility of up to SEK 40 million

Oncology Venture A/S ("Oncology Venture", formerly Medical Prognosis Institute A/S) hereby announces that the ...

author_avatar
NASDAQ Market News

ICU Medical, Inc. Announces Time of Second Quarter 2016 Earnings Call

SAN CLEMENTE, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a ...

author_avatar
NASDAQ Market News